The Only FDA Cleared 24/7 Wearable for Chronic Pain Relief WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (NASDAQ:NURO) today announced that Quell Wearable Pain Relief Technology™ will be featured at the Combined Sections Meeting of the American Physical Therapy Association in Anaheim, CA
The Only FDA Cleared 24/7 Wearable for Chronic Pain Relief WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (NASDAQ:NURO) today announced that Quell Wearable Pain Relief Technology™ will be featured at the American Academy of Pain Medicine (AAPM) Annual Meeting in Palm Springs, California at
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (NASDAQ:NURO) announced today that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, is scheduled to speak at the Source Capital Group's 2016 Disruptive Growth & Healthcare Conference at the Convene Conference Center in New
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (NASDAQ:NURO) today announced that Quell has been selected as a finalist in the 19 th Annual SXSW Interactive Innovation Awards. The SXSW Interactive Innovation Awards celebrate the most inspiring and creative innovations in the connected world.
The Only FDA Cleared 24/7 Wearable for Chronic Pain Relief WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Quell Wearable Pain Relief Technology will be featured at the North Carolina Foot & Ankle Society's Winter Scientific Seminar to be held January 28-31
6,675 Quell ® Devices Shipped, Up 48% Compared to Q3 2015 DPNCheck ® Shipments at All-Time High of 54,300 Biosensors Revenue Up 94% to $2.7 Million Compared to Q4 2014 WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), today reported financial and business highlights for the full
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. ( NASDAQ : NURO) announced today that it plans to issue its 2015 full year and fourth quarter financial results before the opening of the market on January 28, 2016 . The Company will host a conference call at 8:00 a.m., Eastern Time on January
The Only FDA Cleared Wearable Device for 24/7 Chronic Pain Relief Without a Prescription WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Quell Wearable Pain Relief Technology will be exhibited at NY16 - Podiatric Clinical Conference and Exhibition sponsored
Omron Healthcare Leads Local Initiatives WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) today reported regulatory approval in China for DPNCheck ® , a diagnostic test for peripheral neuropathy. DPNCheck is now registered as a Class II Medical Device under the Regulations for
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (Nasdaq: NURO) announced a high level of interest in Quell, the company's over-the-counter, 100% drug free chronic pain relief wearable at CES 2016. Highlights of the Week include: Quell was selected as one of 10 finalists in the CES Last Gadget
